Felip E, Cho BC, Gutierrez V, Alip A, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol 2024 Jun 26:S0923-7534(24)00702-6. doi: 10.1016/j.annonc.2024.
PMID: 38942080